Synthesis and anti-diabetic activity of (RS)-2-ethoxy-3-{4-[2-(4-trifluoro-8methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid

    loading  Checking for direct PDF access through Ovid

Abstract

Aim

To synthesize and study the anti-diabetic activity of (RS)-2-ethoxy-3-{4-[2-(4-trifluoromethanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid (compound I).

Methods

Compound I was prepared in 6 steps, using 4-(2-hydroxy-ethyl)-phenol as the starting material. The in vitro selectivity and potency of target compound I, rosiglitazone and WY-14643 on human PPARα and PPARγ were determined in reporter gene assays. In vivo, rosiglitazone and compound I were administered orally to KKAy mice for 14 d. Insulin tolerance tests and oral glucose tolerance tests were performed on the 10th and 14th day of treatment, respectively. At the end of the treatment, sera were collected for biochemical analysis.

Results

In vitro, compound I significantly activated both PPARα and PPARγ. In vivo, compound I corrected the impaired insulin and glucose tolerance of KKAy mice, and produced a significant reduction in plasma triglyceride levels after 14 d of treatment. The effect produced was significant compared with the control group.

Conclusion

Both in vitro and in vivo anti-diabetic activity studies for compound I were conducted and the data suggest that this compound is a potentially effective anti-diabetic agent.

Related Topics

    loading  Loading Related Articles